Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2020 Report -

·2 min read

The "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2020" drug pipelines have been added to's offering.

Chronic Lymphocytic Leukemia - Pipeline Review, H2 2020, provides an overview of the Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

The Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 6, 61, 71, 3, 10, 67, 8 and 4, respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 15, 13 and 7 molecules, respectively.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (Oncology).

  • The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (Oncology).

For more information about this drug pipelines report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900